The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•21 April 2026•

1 min read

Cavendish Reiterates Buy Rating for IXICO Following 23% Revenue Growth

Canadian flag, a plasma bag, and "GRIFOLS" text on an orange background with medical equipment, microscopes, and vials.

Key Facts

1Cavendish retained its 'buy' rating and 26p price target on IXICO PLC.

2First-half revenues are expected to reach £3.9 million, up 23% year on year.

Broker Cavendish has maintained its 'buy' rating and 26p price target on IXICO PLC following a robust first-half trading update. The company expects first-half revenues to reach £3.9 million, marking a significant 23% increase compared to the same period last year. This growth is primarily driven by a series of new contract wins and the expansion of biomarker analysis services for neurological diseases. Analysts highlight that IXICO has reached a growth inflection point, supported by a surging order book in neuroscience imaging and analytics. The positive momentum reflects the company's strengthening position within the biotech and healthcare sectors. Investors are now focused on how this revenue trajectory will impact long-term profitability and market share.